Evaluate maintains detailed, comprehensive coverage of nearly 7,000 pharmaceutical and biotech companies, including both private and public companies.
Key data highlights
Company summary page
From this page, you can access high-
Company portfolio information
Evaluate offers several ways to analyze a company’s product portfolio, including by the phase of development, historic or future sales value, therapy area, etc. You can open one of the many pre-
In addition to looking at the individual products records, you can also analyze a company’s product portfolio in aggregate. For example, the graph below shows cumulative historic and forecasted sales based on the strategy by which the company came to have rights to the product, allowing for an analysis of the company’s future growth strategies.
Company financials are available via the company summary page, and can be easily exported to Excel for further analysis. Among the financials available are company P&Ls, balance sheet and margin analyses, and free cash flow. EvaluatePharma also offers reports that break out historic and forecast revenues by business segment and revenue type (sales, alliance, royalty, etc.).
In this page
Company related FAQs
What is the methodology for assigning the categorizations for company classifications?
There currently is no standardized or generally accepted definition of categories in the industry, and definitions vary according to the source. In Evaluate we have attempted to classify companies into broad peer groups of similar entities. As with any subjective classification system, the resulting peer group should be viewed as a starting point, and adjusted according to your individual needs. See the attached document below for further details. The order in which the classifications appear for a company (for Example Pfizer is classified as a Global Major (Pharma), Generic, and MedTech) is listed in order of significance.
How does Evaluate display sales information when a company’s fiscal year is different from a calendar year?
In general, for companies with non-